Venture capital investors in TCD campus company Genable Technologies have secured an exit from the loss-making firm through the sale of the business to Nasdaq-quoted Spark Therapeutics. As of February 2015, Genable had capital invested of €6.75m. The two VCs involved were Delta Partners and Fountain Healthcare Partners. In 2011, Delta invested €750,000 and Fountain … Continue reading Genable Technologies Investors Secure Spark Exit